

ILLUMINATE YOUR
DIWALI

WITH PROSPERITY!



Happy Deepawali!



ESPS CAPITAL

Mindful Investing for Sustainable Growth

www.espscapital.com

RECOMMENDATIONS



— About Us —

ESPS Capital brings you right interface into **Financial World** with easy to use **Technology** and well researched Knowledge base. Our well experienced domain experts will help you to meet **Your Financial Goals**. Company is formed with Sole Objective of making sense and ease of Your Investment which can multiply over the years of disciplined investment through various Investment Tools.

Founders and Core Team Members share more than **50+ years of Broking and Financial Product Distribution** experience among each other.

Mindful Investing for Sustainable Growth

We Refer to **ESPS Capital** and Our **Esteemed Customers**.
Our Passion to build our **Customer's Wealth** with our diligence and knowledge keeps us as the topmost choice for **Wealth Creation**.

Diligence | Customer First | Honesty | Integrity



ASHOKK KUMAR SINGH

Founder & Director

- Armed with a Post-Graduate Diploma in Management in Specialization Banking investment & insurance from the Welingkar Institute of Management Development and Research.
- His career spanning 13+ years across leading organizations in the Financial Services domain.
- Ashokk is a first-generation Entrepreneur. Ashok has an in-depth knowledge and understanding of the core domain of Financial Services.
- He is known for his knowledge base on National and Global Capital Markets with finest Portfolio Management.



SANDESH NANDODE

Co-founder and Chief Investment Officer
(SEBI Registered Research Analyst)

- 21 years of experience in Stock Market.
- Expertise in Technical and Fundamental Analysis of Stocks, Commodities and Currencies.
- In depth knowledge and experience of Fund Management.
- Trainer and Mentor, conducted seminars on various topics related to investments and trading in India and abroad.

— Our Well Researched Recommendation —



Happy
Deepawali!

07-11-2020

R E C O M M E N D A T I O N

CMP **2328**TARGET **2750**UPSIDE POTENTIAL **18%**

BSE Code : 524494 | NSE Code : IPCALAB


**FUNDAMENTAL
PARAMETERS**

**FINANCIAL
OVERVIEW**

**SHARE HOLDING
PATTERN**

Face Value (Rs)	2
50 Week High/Low	2460/990
Market Cap (Rs. In Cr.)	29,811.21
EPS (Rs)	76.79
P/E Ratio	30.63
P/B Ratio	8.03
Dividend Yield (%)	0.21

Standalone (Cr)	Forecast		
	Actual Mar-19	Mar-20	Mar-21
Revenue	3633	4367	5240
EBIT	575	800	819
Net Income	454	652	680
Basic EPS	36.01	51.64	53.2
RoE (%)	15.4	17.6	18

Institution	
FII FPI	12.4
Total DII	31.8
Non-Institution	
Promoters	46.07
Others	9.71

INVESTMENT LOGIC

- IPCA has shown a **remarkable 43.61 % growth** in net income during COVID-19 period. IPCA laboratories is one of the leading companies in the production of anti-malarial drug Hydroxychloroquine (HCQ). As per the studies it has been found that HCQ was useful in the treatment of COVID-19 which boosted its demand worldwide.
- IPCA, have boosted the production of **HCQ** by **10 times** on government orders. The government orders came into effect after the Indian Council of Medical Research (ICMR) recommended **HCQ** as prophylaxis for **SARS-CoV-2** infection.
- While there is no drug or vaccine to treat COVID-19 patients at the moment, the Centre for Disease Control and Prevention has recommended a few drugs as therapeutic options for patients with COVID-19.
- As mentioned, Hydroxychloroquine and chloroquine, both anti-malarial drugs, are currently under investigation in clinical trials for SARS-CoV-2 infection.
- The COVID-19 phase will take time to over and by that time HCQ will remain in demand across the globe. The sales of IPCA, both domestic and international, are expected to grow over 18% in coming year.

STRENGTHS

- Company with low debt
- Company with zero promoter pledge
- Strong cash generation ability from core business, cash flow has improved in past 2 years
- Market leader in HCQ production and exports
- Stable company with good management

**WE RECOMMEND
TO BUY.**



Happy
Deepawali!

07-11-2020

R E C O M M E N D A T I O N



CMP

2205

TARGET

2610

UPSIDE POTENTIAL

18.36%



asianpaints

BSE Code : 500820 | NSE Code : ASIANPAINT


**FUNDAMENTAL
PARAMETERS**

**FINANCIAL
OVERVIEW**

**SHARE HOLDING
PATTERN**

Face Value (Rs)	1
50 Week High/Low	2243/1431
Market Cap (Rs. In Cr.)	2,11,680
EPS (Rs)	23.52
P/E Ratio	93.85
P/B Ratio	22.39
Dividend Yield (%)	0.54

Standalone (Cr)	Actual			Forecast		
	Mar-19	Mar-20	Mar-21			
Revenue	19473	20515	22300			
EBIT	3376	3685	4108			
Net Income	2173	2728	3490			
Basic EPS	22.23	27.67	35.42			
RoE	24.11	28.07	33.20			

Institution	
FII FPI	19.84
Total DII	15.46
Non-Institution	
Promoters	52.79
Others	11.9

INVESTMENT LOGIC

- ➔ The Indian paint industry was the second largest in the world in 2019. The sector witnessed significant growth over the past few years. In 2019, the Wholesale Price Index of paints and varnishes stood at 112.7, at its high compared to the last 5 years. The value of India's paint industry was over 57 trillion Indian rupees in 2019.
- ➔ The Indian market was dominated by the decorative segment accounting for about 75 percent of the market share compared to industrial segment which had just over 25 percent of the share. Less technical know-how and the involvement of organized as well as unorganized players contributed to this major difference in market shares.

MARKET LEADER

- ➔ **Asian Paints** was the market leader in 2019 in India, with a market share of 39%. In the organized segment, Asian Paints led the

decorative market segment. As of 2019, the Indian paint industry saw around 12 percent growth in its output volumes and about 15 percent growth in terms of its total value. Future growth in the industry is likely to grow at little more pace as lockdowns getting lifted across the country, this will regain the disposable income. Good monsoon this year will bring the much necessary liquidity in the market specially in automotive and real estate segment. This will further increase the demand of paints.

- ➔ As of 31 March 2020, net income of Asian Paints grew by 25.48%, income operations grew by 7.40%, revenues up by 5.00% and the gross profit is up by 10.85%.

WE RECOMMEND TO BUY.



07-11-2020

R E C O M M E N D A T I O N



CMP

277

TARGET

374

UPSIDE POTENTIAL

35%



Knowledge . Innovation . Excellence

BSE Code : 540222 | NSE Code : LAURUSLABS


**FUNDAMENTAL
PARAMETERS**

**FINANCIAL
OVERVIEW**

**SHARE HOLDING
PATTERN**

Face Value (Rs)	2
50 WeekHigh/Low	345/59
Market Cap (Rs. In Cr.)	15455
EPS (Rs)	10.95
P/E Ratio	26.32
P/B Ratio	8.51
Dividend Yield (%)	0.17

Standalone (Cr)	Actual		Forecast	
	Mar-19	Mar-20	Mar-21	
Revenue	2251	2802	3362	
EBIT	206	391	390	
Net Income	94	267	200	
Basic EPS	8.94	25.03	24	
RoE	5.97	14.7	12	

Institution	
FII FPI	16.06
Total DII	32.39
Non-Institution	
Promoters	32.13
Others	19.42

INVESTMENT LOGIC

- Laurus Laboratories** is a leading developer and manufacturer of generic **APIs in high growth** therapeutic areas of **Anti Retro Viral, Oncology and Hepatitis Ci**. Laurus is amongst the top suppliers of APIs in the ARV therapeutic area to formulation companies catering to the **fast-growing** 'donor-funded access to medicines' markets in Sub-Saharan Africa, South-East Asia and Latin America.
- Laurus Lab** possess strong R&D capabilities and process chemistry skills. **There are more than 750 scientists at R&D centres**, which constitutes a quarter of total employee strength of Laurus Lab. Long standing relationships of Laurus Lab with multinational companies is an added advantage.
- Since the inception in 2005**, Laurus Lab's revenues have grown at a **CAGR of 41.1% from FY 2012 to FY 2016**. The revenues have grown by 25% by September 2020. EPS has grown by whooping 180% during same period in 2020. **RoE stood at 14.7% up by 146.2%** and cash flow from operations are growing consistently.

STRENGTHS

- High Piotroski score indicates strong financials of the company**
- Rising return on equity (RoE), Momentum, and Earnings Yield**
- Company with decreasing promoter pledge**
- FII/FPI are increasing their shareholdings**
- Growth in Operating Profit with increase in Operating Margins**

**WE RECOMMEND
TO BUY.**



Happy
Deepawali!

07-11-2020

R E C O M M E N D A T I O N

CMP **302.80**TARGET **382**UPSIDE POTENTIAL **26%**

BSE Code : 511243 | NSE Code : CHOLAFIN

**FUNDAMENTAL
PARAMETERS****FINANCIAL
OVERVIEW****SHARE HOLDING
PATTERN**

Face Value (Rs)	2
50 Week High/Low	349/117
Market Cap (Rs. In Cr.)	24003
EPS (Rs)	15.79
P/E Ratio	18.54
P/B Ratio	2.94
Dividend Yield (%)	0.58

Standalone (Cr)	Actual			Forecast		
	Mar-19	Mar-20	Mar-21			
Revenue	6992	8652	10600			
EBIT	5411	6177	7040			
Net Income	1186	1052	1168			
Basic EPS	75.87	13.37	20.72			
RoE	19.2	12.87	21.23			

Institution	
FII FPI	11.9
Total DII	29.72
Non-Institution	
Promoters	51.56
Others	6.73

INVESTMENT LOGIC

Chola started their business as an equipment financing company and has emerged as a comprehensive financial services provider offering vehicle finance, home loans, home equity loans, SME loans, investment advisory services, stock broking and variety of other financial services. Chola operates from 1098 branches across India with assets under management above INR 63,501 crores. Cholamandalam Securities Limited (CSEC), Cholamandalam Home Finance Limited (CHFL) are the subsidiaries of Chola.

CHOLA'S POSITION POST COVID-19:

- Chola shall continue to focus on retail ticket size loans to reduce concentration risk
- Revision of SARFAESI limit to 50 lakhs will positively impact chola
- Chola's focus on tier 2, 3 cities and retail/trader segment will help bounce back
- Chola has very low exposure to commercial properties
- Chola does not have Construction Finance exposure
- Chola does not have material under construction exposure to developer supplied houses
- 90% of assets purchased from Chola's home loan are in tier 2,3,4 cities- expected to have lesser impact of COVID crisis.
- End use driven funding to home buyers

STRENGTHS

- 477.2% returns over 4.5 years**
- Effectively using its capital to generate consistent profits, RoCE improving in last 2 years**
- Company with zero promoter pledge**
- FII/FPI and Institutions increasing their shareholdings**
- Mutual Funds increased their shareholding in last quarter**

**WE RECOMMEND
TO BUY.**



OUR STORY

Why the name is **ESPS**..

The Name is Inspired by our philosophy of **Mindful Investment**, these are the **Four Pertinent** pointers in selecting a Winner company of the Future, which are **Easy Sustainable Profitable** and **Scalable** - **ESPS**, A constant reminder of Mindful Investing.

The logo is a **Three Pointed Star** which suggests Ever Progressive Attitude, Dedication and Diligence for Overall Growth of the Company and its Valuable Customers.



— **ESPS GROUP** —



ESPS CAPITAL



**ESPS
FinServ**



**ESPS REALTY
ADVISORS**

DISCLAIMER: All Research Reports are for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to the investor. It is only for private circulation and use. The Research Report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of this Research Report.

The Research Report should not be reproduced or redistributed to any other person(s) in any form without prior written permission of the **ESPS CAPITAL**. The contents of this material are general and are neither comprehensive nor inclusive. Neither **ESPS CAPITAL** nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this Research Report.

It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions.

Please note that **ESPS CAPITAL** its affiliates, Research Analyst, officers, directors, and employees, including persons involved in the preparation or issuance of this Research Report:

- a. from time to time, may have long or short positions in, and buy or sell the securities thereof, of the subject company(ies) mentioned here in; OR
- b. be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender/borrower to such subject company(ies).

SEBI Registered Research Analyst: SANDESH NANDODE, Registration No.: INH000006475

Data Source : Company website, Moneycontrol.com, Screener.in



ESPS CAPITAL



EQUITY



PMS



MUTUAL FUND



COMMODITY & CURRENCY



LOANS



INSURANCE





ALTERNATIVE INVESTMENT FUND



IPO

Manage your FINANCE At your FINGERTRIPS



www.espscapital.com

ESPS Capital is a registered trademark of TSPL.

SEBI Registration No: INZ000009530 | CIN Number: U74899DL1995PTC068523

NSE Member Code: 14940 | BSE Member Code: 6621 | CDSL: IN-DP-CDSL- IN-DP-229-2016 | NSDL: IN-DP-NSDL- NA

Corporate Office : 504, Antriksh Thakur House, Marol Makawana Road, Marol Andheri East, Mumbai - 400059

Registered Office: 214, 54-B Block, Community Centre, Mahatta Tower, Janakpuri, Delhi-110058

Toll- Free No: 18002676520